Valuation : Sygnis SA

Market Cap 33.94M 9.07M 7.82M 7.33M 6.69M 12.61M 867M 12.65M 86.98M 438M 34.07M 33.33M 1.45B P/E 2024 *
-
P/E 2025 174x
Enterprise Value 36.65M 9.8M 8.44M 7.92M 7.23M 13.61M 936M 13.66M 93.92M 473M 36.79M 35.99M 1.57B EV / Sales 2024
1.44x
EV / Sales 2025 5.47x
Free-Float
38.48%
Yield 2024 *
-
Yield 2025 -
1 week-8.77%
Current month-7.14%
1 month-7.14%
3 months-17.46%
6 months-33.76%
Current year-51.85%
1 week 1
Extreme 1
1.11
1 month 1
Extreme 1
1.26
Current year 1
Extreme 1
3
1 year 1
Extreme 1
3.8
3 years 0.28
Extreme 0.28
3.8
5 years 0.28
Extreme 0.28
3.8
10 years 0.18
Extreme 0.176
3.8
Manager TitleAgeSince
Chief Executive Officer - 2016-12-31
Chief Tech/Sci/R&D Officer - 2018-10-31
Sales & Marketing - 2019-12-31
Director TitleAgeSince
Chairman - 2025-10-28
Director/Board Member - 2025-10-28
Chairman - -
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-8.77%-31.58%-0.95% 9.07M
-0.78%-1.42%+2.96%+20.82% 50.47B
-6.00%-0.75%+447.48%+524.26% 44.56B
-0.24%+0.74%+37.18%+16.57% 43.08B
-1.55%-2.07%+19.83%+73.63% 41.7B
-0.31%-0.83%+19.47%+48.24% 33.21B
-1.79%-3.24%+26.32%+121.63% 16.77B
-0.58%-2.12% - - 16.28B
-0.88%-0.66%+11.63%+28.71% 14.58B
-1.66%-1.25%+78.49%+39.02% 13.92B
Average -1.38%-1.79%+67.98%+96.88% 27.46B
Weighted average by Cap. -1.70%-1.21%+96.27%+126.98%

Financials

2024 2025
Net sales 9.8M 2.62M 2.26M 2.12M 1.93M 3.64M 250M 3.65M 25.12M 126M 9.84M 9.62M 419M 11.33M 3.03M 2.61M 2.45M 2.24M 4.21M 290M 4.22M 29.05M 146M 11.38M 11.13M 485M
Net income -11.29M -3.02M -2.6M -2.44M -2.23M -4.19M -289M -4.21M -28.94M -146M -11.34M -11.09M -483M 404K 108K 93.14K 87.33K 79.72K 150K 10.33M 151K 1.04M 5.22M 406K 397K 17.29M
Net Debt 4.3M 1.15M 990K 928K 847K 1.6M 110M 1.6M 11.01M 55.43M 4.31M 4.22M 184M 2.71M 724K 624K 585K 534K 1.01M 69.24M 1.01M 6.94M 34.95M 2.72M 2.66M 116M
Logo Sygnis SA
Sygnis SA is a Poland-based company primarily engaged in the Research and Development (R&D) activities. The Company is active in four segments: Bioconvergence, Nanotechnology, Power Engineering, and New Incremental Technologies. Bioconvergence is a segment in which research is conducted to prevent the shortage of organs for transplants by bioprinting organs and creating bionic models for drug testing. The Nanotechnology segment is focused on using solutions from the field of photoelectron spectroscopy, and critical atomic force microscopy in casual products. The Power Engineering segment is focused on new methods of energy storage for renewable energy and other sources. New Incremental Technologies is focused on the development of solutions regarding 3D printing. The Company cooperates with over 85 specialists such as physicists, mechatronics, chemists, engineers, designers, and sociologists, and is involved in multiple projects.
Employees
24
Date Price Change Volume
26-08-28 PLN 1.040 0.00% 63,093
26-08-27 PLN 1.040 -4.59% 87,571
26-08-26 PLN 1.090 +0.93% 38,471
26-08-25 PLN 1.080 -1.82% 10,358
26-08-24 PLN 1.100 -3.51% 50,875